Recruiting

Bioresorbable Airway Splint

Sponsor:

University of Michigan

Code:

NCT06406452

Conditions

Tracheobronchomalacia

Eligibility Criteria

Sex: All

Age: 0 - 3

Healthy Volunteers: Not accepted

Interventions

Bioresorbable Tracheobronchial Splint

Study Details

Brief summary:

The purpose of this study is to learn if a three-dimensional (3D) printed airway splint device made to hold open a collapsing airway is a safe and effective treatment of Tracheobronchomalacia (TBM) in children.

The airway splint is bioresorbable, meaning the child's body will absorb the splint over about five years.

Conditions

Tracheobronchomalacia

Study ID

NCT06406452

Start date

Jan 7, 2025

Status verified date

Jan, 2026

Completion date

Mar, 2034

Anticipated

Primary completion date

Sep, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 3

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Subject must have clinically significant tracheobronchomalacia and:

1. be unable to wean off of mechanical ventilation, and/or
2. be currently dependent on a tracheostomy tube, and/or
3. meet current indications for a tracheostomy or another surgical intervention for TBM
  • Subjects must have a life expectancy of at least 2 years, exclusive of TBM
  • Subjects must have a parent or legal guardian capable of giving consent on behalf of the subject, and must be willing and able to complete the requirements of clinical trial follow-up
  • Subject must have a physician willing to provide follow-up clinical data, including a bronchoscopy at 2 years
  • Subjects must be greater than 1 week of age and less than 4 years of age. (Infant subjects born preterm, with low birth weight, or small for gestational age are eligible for trial enrollment if their comorbidities do not present a contraindication to surgical intervention for subjects TBM and airways are of a size that can appropriately be treated with the range of splint sizes offered in this clinical trial)

Patency-Based Pre-Operative Inclusion Criteria:

\- Subjects must have tracheobronchomalacia in the trachea, left main bronchus, or right main bronchus a minimum patency of less than 50% in one of these regions

  • Screening: In order for a subject to be sent to a clinical trial site for evaluation for the clinical trial, a subject must have tracheobronchomalacia with evidence of less than 50% minimum patency based on a Computed Tomography Scan (CT), Magnetic resonance imaging (MRI), or bronchoscopic exam at referring institution confirmed by an imaging or operative note from the local physician.
  • At Enrollment: The subject must have tracheobronchomalacia with minimum patency of less than 50% in the trachea and/or left mainstem bronchus and/or right mainstem bronchus, based on expiration/inspiration CT performed at a clinical trial site performed during visit 1

Intra-Operative Inclusion Criteria:

\- The surgeon can safely dissect out the malacic trachea or bronchus/bronchi in order to place the splint

Pre-Operative Exclusion Criteria:

  • Subject has significant fixed anatomic tracheal stenosis
  • Subject has untreated complete tracheal rings
  • Subject has single-lung anatomy
  • Subject has single-ventricle cardiac anatomy
  • Subject has external compression due to active malignancy, active infection, or an undrained cyst
  • Subject has a non-bioresorbable airway stent. Recent removal of any stent will require verification of integrity of the airway wall
  • Subject has a contraindication to surgery other than airway compromise
  • Subject has a known hypersensitivity to polycaprolactone or hydroxyapatite, and/or a previous unusual reaction to bioresorbable sutures
  • Subject has a genetic defect of cartilage formation
  • Subject has significant bronchomalacia distal to the mainstem as the predominant source of subject's airway obstruction
  • Membranous posterior wall intrusion is the predominant form of collapse

Study Design

Enrollment

35 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Bioresorbable Tracheobronchial Splint

Participants are admitted to the hospital for this assessment and placement of the splint.

Interventions

Bioresorbable Tracheobronchial Splint

Subjects will have several imaging and bronchoscopic studies and the placement of the splint will require an open-chest surgery to implant the airway splint (s).

The Materialise Bioresorbable Tracheobronchial Splint is designed for an individual subject based on Computed Tomography (CT) scans taken using a specific scan protocol. Based on these 3D models, a pre-operative plan is discussed between the Materialise engineering team and the treating surgeon(s) to determine the locations and required dimensions of the splint(s). Each subject may receive up to four splints positioned on subject's trachea or mainstem bronchi.

Subjects will also have several follow-up visits, and parents will be expected to regularly fill out questionnaires.

Primary outcome measure

  • The proportion of subjects that survive to 6 months post-splinting [ Time Frame: 6 months post splint implantation ]
  • The Proportion of splinted regions with equal or greater than (≥) 50% average patency at approximately 4 weeks visit (window ±2 weeks) after splint implantation [ Time Frame: Approximately 4 weeks (±2 weeks) post splint implantation ]

Central Contacts and Locations

Central contacts

Locations

University of Michigan

Recruiting

Ann Arbor, Michigan, United States, 48109

Contacts

Principal Investigator:

Richard G Ohye, MD

More Information

Sponsor

University of Michigan

Last update posted

Jan 21, 2026

Last verified

Jan, 2026

Keywords

  • Children
  • Airway splint
  • Three-dimensional printed
  • Multi-stie

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of Michigan on 2026-01-21.